hxy5msbf

Property	Value
?:abstract	BACKGROUND: Understanding of the true asymptomatic rate of infection of SARS-CoV-2 is currently limited, as is understanding of the population-based seroprevalence after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms. METHODS: We undertook enzyme linked immunosorbent assay characterisation of IgM and IgG responses against SARS-CoV-2 spike glycoprotein and nucleocapsid protein of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged 19-86 (median age 48; 85% female). 382 participants completed prospective logging of 14 COVID-19 related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 previously modelled on PCR positive individuals from a dataset of over 2 million. FINDINGS: We demonstrated a seroprevalence of 12% (51 participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic, and 16 (27%) were asymptomatic for core COVID-19 symptoms: fever, cough or anosmia. Specificity of anosmia for seropositivity was 95%, compared to 88% for fever cough and anosmia combined. 34 individuals in the cohort were predicted to be Covid-19 positive using the App algorithm, and of those, 18 (52%) were seropositive. INTERPRETATION: Seroprevalence amongst adults from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic throughout the study. Anosmia demonstrated the highest symptom specificity for SARS-CoV-2 antibody response. FUNDING: NIHR BRC, CDRF, ZOE global LTD, RST-UKRI/MRC.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/hxy5msbf_hasAnnotation_C0010200> <https://research.tib.eu/covid-19/entity/hxy5msbf_hasAnnotation_C0015967> <https://research.tib.eu/covid-19/entity/hxy5msbf_hasAnnotation_C1421479> <https://research.tib.eu/covid-19/entity/hxy5msbf_hasAnnotation_C1425219> <https://research.tib.eu/covid-19/entity/hxy5msbf_hasAnnotation_C1457887> <https://research.tib.eu/covid-19/entity/hxy5msbf_hasAnnotation_C1540289> <https://research.tib.eu/covid-19/entity/hxy5msbf_hasAnnotation_C1706005> <https://research.tib.eu/covid-19/entity/hxy5msbf_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Wells%2C_Philippa_M%3B_Doores%2C_Katie_J%3B_Couvreur%2C_Simon%3B_Nunez%2C_Rocio_Martinez%3B_Seow%2C_Jeffrey%3B_Graham%2C_Carl%3B_Acors%2C_Sam%3B_Kouphou%2C_Neophytos%3B_Neil%2C_Stuart_J_D%3B_Tedder%2C_Richard_S%3B_Matos%2C_Pedro_M%3B_Poulton%2C_Kate%3B_Lista%2C_Maria_Jose%3B_Dickenson%2C_Ruth_E%3B_Sertkaya%2C_Helin%3B_Maguire%2C_Thomas_J_A%3B_Scourfield%2C_Edward_J%3B_Bowyer%2C_Ruth_C_E%3B_Hart%2C_Deborah%3B_O039%2C%3B_Byrne%2C_Aoife%3B_Steel%2C_Kathryn_J_A%3B_Hemmings%2C_Oliver%3B_Rosadas%2C_Carolina%3B_McClure%2C_Myra_O%3B_Capedevilla-Pujol%2C_Joan%3B_Wolf%2C_Jonathan%3B_Ourselin%2C_Sebastien%3B_Brown%2C_Matthew_A%3B_Malim%2C_Michael_H%3B_Spector%2C_Tim%3B_Steves%2C_Claire_J>
?:journal	J_Infect
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/hxy5msbf_HAS_C1457887_PREDISPOSES_C5203670>
?:source	WHO
?:title	Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#866901
?:year	2020

Property

Value

?:abstract

BACKGROUND: Understanding of the true asymptomatic rate of infection of SARS-CoV-2 is currently limited, as is understanding of the population-based seroprevalence after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms. METHODS: We undertook enzyme linked immunosorbent assay characterisation of IgM and IgG responses against SARS-CoV-2 spike glycoprotein and nucleocapsid protein of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged 19-86 (median age 48; 85% female). 382 participants completed prospective logging of 14 COVID-19 related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 previously modelled on PCR positive individuals from a dataset of over 2 million. FINDINGS: We demonstrated a seroprevalence of 12% (51 participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic, and 16 (27%) were asymptomatic for core COVID-19 symptoms: fever, cough or anosmia. Specificity of anosmia for seropositivity was 95%, compared to 88% for fever cough and anosmia combined. 34 individuals in the cohort were predicted to be Covid-19 positive using the App algorithm, and of those, 18 (52%) were seropositive. INTERPRETATION: Seroprevalence amongst adults from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic throughout the study. Anosmia demonstrated the highest symptom specificity for SARS-CoV-2 antibody response. FUNDING: NIHR BRC, CDRF, ZOE global LTD, RST-UKRI/MRC.

is ?:annotates of